Advertisement

Hepatology International

, Volume 8, Issue 4, pp 582–587 | Cite as

Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae: a retrospective cohort study

  • Min Jae Kim
  • Kyoung-Ho Song
  • Nak-Hyun Kim
  • Pyoeng Gyun Choe
  • Wan Beom Park
  • Ji Hwan Bang
  • Eu Suk Kim
  • Sang Won Park
  • Hong Bin Kim
  • Hyo-Suk Lee
  • Myoung-don Oh
  • Nam Joong KimEmail author
Original Article

Abstract

Purpose

The aim of this study was to (1) evaluate the clinical outcomes of spontaneous bacterial peritonitis (SBP) due to extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae (EK) and (2) investigate the relationship between the adequacy of initial antibiotic treatments and patient outcomes.

Methods

We conducted a retrospective cohort study of cirrhotic patients with SBP caused by EK. We evaluated the 30-day mortality rate and used Cox proportional hazard models to identify risk factors for mortality.

Results

Between January 2006 and December 2012, a total of 231 episodes of SBP due to EK were recorded. Among them, 52 were caused by ESBL-producing EK (ESBL-EK). The 30-day mortality rate was significantly higher in patients with SBP due to ESBL-EK than in those with non-ESBL-producing EK (non-ESBL-EK) (34.6 vs. 18.4 %, respectively; p = 0.013). Multivariate analysis revealed that ESBL production [adjusted HR (aHR) 1.82, 95 % confidence interval (CI) 1.00–3.31], nosocomial infection (aHR 2.24, 95 % CI 1.26–3.95), septic shock (aHR 4.84, 95 % CI 2.70–8.65), higher Child-Pugh score (aHR 1.57, 95 % CI 1.28–1.92), and higher Charlson comorbidity index (aHR 1.37, 95 % CI 1.15–1.64) were independent risk factors for 30-day mortality in the total cohort. When we analyzed patients with SBP due to ESBL-EK separately, septic shock (aHR 3.64, 95 % CI 1.40–9.77), accompanying bacteremia (aHR 3.71, 95 % CI 1.37–10.08), and hepatocellular carcinoma (aHR 3.21, 95 % CI 1.20–8.56) were independent risk factors.

Conclusions

Both 7- and 30-day mortalities for SBP due to ESBL-EK were significantly higher than for SBP due to non-ESBL-EK. Initial antibiotic choice was not associated with poor clinical outcomes in patients with SBP due to ESBL-EK.

Keywords

Spontaneous bacterial peritonitis ESBL Antibiotics 

Notes

Acknowledgements

There was no financial support for this study.

Compliance with ethical requirements and Conflict of interest

This study was approved by the institutional review board of the Seoul National University Hospital Medical Center (protocol no. 1305-630-491) according to the Helsinki Declaration of 1975, as revised in 2008. Informed consent was waived by the board. Min Jae Kim, Kyoung-Ho Song, Nak-Hyun Kim, Pyoeng Gyun Choe, Wan Beom Park, Ji Hwan Bang, Eu Suk Kim, Sang Won Park, Hong Bin Kim, Hyo-Suk Lee, Myoung-don Oh, and Nam Joong Kim declare that they have no conflict of interest.

References

  1. 1.
    Heo J, Seo YS, Yim HJ, Hahn T, Park SH, Ahn SH, et al. Clinical features and prognosis of spontaneous bacterial peritonitis in Korean patients with liver cirrhosis: a multicenter retrospective study. Gut Liver 2009;3(3):197–204PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Cheong HS, Kang CI, Lee JA, Moon SY, Joung MK, Chung DR, et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009;48(9):1230–1236PubMedCrossRefGoogle Scholar
  3. 3.
    Song KH, Jeon JH, Park WB, Park SW, Kim HB, Oh MD, et al. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case–control study. BMC Infect Dis 2009;9:41PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Badawy AA, Zaher TI, Sharaf SM, Emara MH, Shaheen NE, Aly TF. Effect of alternative antibiotics in treatment of cefotaxime resistant spontaneous bacterial peritonitis. World J Gastroenterol 2013;19(8):1271–1277PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Pleguezuelo M, Benitez JM, Jurado J, Montero JL, De la Mata M. Diagnosis and management of bacterial infections in decompensated cirrhosis. World J Hepatol 2013;5(1):16–25PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Ginès P, Angeli P, Lenz K, Møller S, Moore K, Moreau R, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53(3):397–417CrossRefGoogle Scholar
  7. 7.
    Park YH, Lee HC, Song HG, Jung S, Ryu SH, Shin JW, et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol 2003;18(8):927–933PubMedCrossRefGoogle Scholar
  8. 8.
    Park MK, Lee JH, Byun YH, Lee H, Gwak GY, Choi MS, et al. Changes in the profiles of causative agents and antibiotic resistance rate for spontaneous bacterial peritonitis: an analysis of cultured microorganisms in recent 12 years. Korean J Hepatol 2007;13(3):370–377PubMedCrossRefGoogle Scholar
  9. 9.
    Alexopoulou A, Papadopoulos N, Eliopoulos DG, Alexaki A, Tsiriga A, Toutouza M, et al. Increasing frequency of gram-positive cocci and gram-negative multidrug-resistant bacteria in spontaneous bacterial peritonitis. Liver Int 2013;33(7):975–981PubMedCrossRefGoogle Scholar
  10. 10.
    Fernandez J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012;55(5):1551–1561PubMedCrossRefGoogle Scholar
  11. 11.
    Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Oh MD, et al. Clinical outcome of bacteremic spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Korean J Intern Med 2004;19(3):160–164PubMedGoogle Scholar
  12. 12.
    Ariza X, Castellote J, Lora-Tamayo J, Girbau A, Salord S, Rota R, et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012;56(4):825–832PubMedCrossRefGoogle Scholar
  13. 13.
    Song JY, Jung SJ, Park CW, Sohn JW, Kim WJ, Kim MJ, et al. Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired. J Korean Med Sci 2006;21(4):666–671PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Singh N, Wagener MM, Gayowski T. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clin Microbiol Infect 2003;9(6):531–537PubMedCrossRefGoogle Scholar
  15. 15.
    Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement (CLSI Document M100-20). Wayne, PA: Clinical Laboratory Standards Institute; 2010Google Scholar
  16. 16.
    Nakamura T, Funayama H, Yoshimura A, Tsuruya Y, Saito M, Kawakami M, et al. Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. Int J Cardiol 2006;106(2):191–195PubMedCrossRefGoogle Scholar
  17. 17.
    Chang L, Bastian I, Warner M. Survey of Klebsiella pneumoniae bacteraemia in two South Australian hospitals and detection of hypermucoviscous phenotype and magA/rmpA genotypes in K. pneumoniae isolates. Infection 2013;41(2):559–563PubMedCrossRefGoogle Scholar
  18. 18.
    Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48(12):4574–4581PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002;28(12):1718–1723PubMedCrossRefGoogle Scholar
  20. 20.
    Cho JH, Park KH, Kim SH, Bang JH, Park WB, Kim HB, et al. Bacteremia is a prognostic factor for poor outcome in spontaneous bacterial peritonitis. Scand J Infect Dis 2007;39(8):697–702PubMedCrossRefGoogle Scholar
  21. 21.
    Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34(2):135–146PubMedCrossRefGoogle Scholar
  22. 22.
    Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46(5):1481–1491PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Lin JN, Chen YH, Chang LL, Lai CH, Lin HL, Lin HH. Clinical characteristics and outcomes of patients with extended-spectrum beta-lactamase-producing bacteremias in the emergency department. Intern Emerg Med 2011;6(6):547–555PubMedCrossRefGoogle Scholar
  24. 24.
    Peralta G, Lamelo M, Alvarez-Garcia P, Velasco M, Delgado A, Horcajada JP, et al. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis 2012;12:245PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Park SH, Choi SM, Lee DG, Kim J, Choi JH, Kim SH, et al. Emergence of extended-spectrum beta-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes. Microb Drug Resist 2011;17(4):537–544PubMedCrossRefGoogle Scholar
  26. 26.
    Tuon FF, Kruger M, Terreri M, Penteado-Filho SR, Gortz L. Klebsiella ESBL bacteremia-mortality and risk factors. Braz J Infect Dis 2011;15(6):594–598PubMedCrossRefGoogle Scholar
  27. 27.
    Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, et al. Clinical impact of extended-spectrum beta-lactamase-producing Enterobacteriaceae in patients with biliary tract infection. Dig Dis Sci 2013;58(3):841–849PubMedCrossRefGoogle Scholar
  28. 28.
    Qureshi ZA, Paterson DL, Peleg AY, Adams-Haduch JM, Shutt KA, Pakstis DL, et al. Clinical characteristics of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type beta-lactamases. Clin Microbiol Infect 2012;18(9):887–893PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2014

Authors and Affiliations

  • Min Jae Kim
    • 1
  • Kyoung-Ho Song
    • 1
  • Nak-Hyun Kim
    • 1
  • Pyoeng Gyun Choe
    • 1
  • Wan Beom Park
    • 1
  • Ji Hwan Bang
    • 1
  • Eu Suk Kim
    • 1
  • Sang Won Park
    • 1
  • Hong Bin Kim
    • 1
  • Hyo-Suk Lee
    • 1
  • Myoung-don Oh
    • 1
  • Nam Joong Kim
    • 1
    Email author
  1. 1.Department of Internal Medicine, College of MedicineSeoul National UniversitySeoulRepublic of Korea

Personalised recommendations